title: Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
abstract: OBJECTIVE
  The early natural history of epithelial ovarian carcinoma remains poorly understood. Mutation of the TP53 gene is common in advanced-stage (III-IV) ovarian cancers, but less well described in early stage (I-II) tumors. The purpose of this study was to perform a comprehensive analysis of TP53 mutation and p53 expression status in early stage ovarian carcinomas.
  
  
  METHODS
  Seventy-three cases of various histologic types, including 46 stage I and 27 stage II tumors, were subjected to direct sequence analysis of the entire TP53 coding region and exon-intron junctions as well as immunohistochemical assessment of p53 expression.
  
  
  RESULTS
  Overall, mutations were identified in 24 of 73 (34%) cases. However, a significant difference in the distribution of mutations among histologic types was observed; TP53 mutations were present in 14 of 21 (67%) serous cancers and 11 of 52 (21%) non-serous cancers (P = 0.0002). Mutations were equally common between stage I and stage II tumors of serous histology. With respect to the correlation between TP53 mutation and p53 immunopositivity, the sensitivity (58%), specificity (71%), positive predictive value (64%), and negative predictive value (83%) were not sufficiently robust to justify use of p53 expression as a surrogate or screen for mutation.
  
  
  CONCLUSIONS
  These data indicate that TP53 mutation is common in early stage ovarian carcinomas of serous histology, with a mutation frequency comparable to that reported for advanced-stage tumors, and is therefore likely to occur early in the progression of the most common histologic variant of ovarian carcinoma.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: Mario M
authors.initials: MM
authors.lastname: Leitao
authors.forename: Robert A
authors.initials: RA
authors.lastname: Soslow
authors.forename: Rebecca N
authors.initials: RN
authors.lastname: Baergen
authors.forename: Narciso
authors.initials: N
authors.lastname: Olvera
authors.forename: Crispinita
authors.initials: C
authors.lastname: Arroyo
authors.forename: Jeff
authors.initials: J
authors.lastname: Boyd
mesh_terms: D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D016368:Frameshift Mutation; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D020125:Mutation, Missense; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D016159:Tumor Suppressor Protein p53